William P. Sheridan
2021
Compensation breakdown
| Bonus | $21,224 |
|---|---|
| Non-Equity Incentive Plan | $238,770 |
| Option Awards | $1,287,761 |
| Salary | $530,600 |
| Stock Awards | $400,050 |
| Other | $52,826 |
| Total | $2,531,231 |
Sheridan received $1.3M in option awards, accounting for 51% of the total pay in 2021.
Sheridan also received $21.2K in bonus, $238.8K in non-equity incentive plan, $530.6K in salary, $400.1K in stock awards and $52.8K in other compensation.
Rankings
In 2021, William P. Sheridan's compensation ranked 5,098th out of 12,415 executives tracked by ExecPay. In other words, Sheridan earned more than 58.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,098 out of 12,415 | 59th |
Division Manufacturing | 2,148 out of 5,505 | 61st |
Major group Chemicals And Allied Products | 923 out of 2,375 | 61st |
Industry group Drugs | 825 out of 2,096 | 61st |
Industry Biological Products, Except Diagnostic Substances | 206 out of 449 | 54th |
Pay ratio
| William P. Sheridan's Pay | $2,531,231 |
|---|---|
| Median Employee's Pay | $273,522 |
| Pay Ratio | 9to 1 |
In 2021, the annual total compensation of William P. Sheridan was $2,531,231.
The annual total compensation of the median employee at BioCryst Pharmaceuticals was $273,522.
The ratio of William P. Sheridan's pay to the pay of median employee was therefore 9 to one.
Sheridan's colleagues
We found five more compensation records of executives who worked with William P. Sheridan at BioCryst Pharmaceuticals in 2021.
2021
Megan Sniecinski
BioCryst Pharmaceuticals
Former Chief Business Officer
2021
Jon Stonehouse
BioCryst Pharmaceuticals
Chief Executive Officer
2021
Helen Thackray
BioCryst Pharmaceuticals
Chief R&D Officer
2021
Anthony Doyle
BioCryst Pharmaceuticals
Chief Financial Officer
2021
Yarlagadda Babu
BioCryst Pharmaceuticals